Iterum Therapeutics Announces U.S. Commercial Launch of ORLYNVAHTM Targeted for Q4 2025 in Partnership with EVERSANA
11/6 13:14
Iterum Therapeutics announces ORLYNVAHTM's commercial launch in the U.S. for urinary tract infections by Q4 2025....
11/6 13:14
Iterum Therapeutics announces ORLYNVAHTM's commercial launch in the U.S. for urinary tract infections by Q4 2025....